ASSOCIATION OF MTHFR A1298C POLYMORPHISMWITH BREAST CANCER AND/OR OVARIAN CANCER RISK: AN UPDATED META-ANALYSIS by Liu, Wei et al.
Liu et al ., Afr J Tradit Complement Altern Med. (2016) 13(5):72-86 
  doi:10.21010/ajtcam.v13i5.11 
72 
 
ASSOCIATION OF MTHFR A1298C POLYMORPHISM WITH BREAST CANCER AND/OR OVARIAN 
CANCER RISK: AN UPDATED META-ANALYSIS 
 
Wei Liu1#, Yi Li2#, Rui Li3, Xiao Han4, Ying Ma5, Bin Liu6*#, Xiangzhen Kong7*# 
 
1The School of Nuclear Science and Technology Lanzhou University, School/Hospital of Stomatology Lanzhou 
University, Lanzhou City 730000, Gansu Province, China. 2The co-first author, School of Basic Medical Sciences, 
Lanzhou University, Lanzhou City 730000, Gansu Province, China. 3Lanzhou University School of Stomatology, 
Lanzhou City 730000, Gansu Province, China.4Gansu University of Traditional Chinese Medicine, Lanzhou City 
730000, Gansu Province, China. 5School of Basic Medical Sciences, Lanzhou University, Lanzhou City 730000, 
Gansu Province, China. 6The second corresponding author, the School of Nuclear Science and Technology Lanzhou 
University, School/hospital of Stomatology Lanzhou University, Lanzhou City 730000, Gansu Province, China. 7The 
first corresponding author, Research Department, Qinghai University Affiliated Hospital, Xining City 810000, 
Qinghai Provincekongxzh12@aliyun.com. 
 
# Authors contributed equally to this work. 
 
Corresponding authors E-mail: kongxzh12@aliyun.com  liubkq@lzu.edu.cn  
 
 
Abstract 
 
Background: Recent years have witnessed the discovery of similar gene variations between breast cancer and ovarian cancer, inherited breast 
and ovarian cancer in particular. A large number of case-control studies have been conducted to explore the association of 
Methylenetetrahydrofolate Reductase (MTHFR) A1298C polymorphism with breast cancer and/or ovarian cancer risk. However, the results are 
still inconsistent and inconclusive. Consequently, we performed a meta-analysis to evaluate the association between MTHFR A1298C 
polymorphism and breast, ovarian cancer risk.  
Materials and Methods: A comprehensive retrieval was conducted in the electronic database of PubMed, Web of Science and Chinese National 
Knowledge Infrastructure (CNKI) until June 2015 to identify eligible studies. A total of 35 studies which examined the association of MTHFR 
A1298C polymorphism with breast cancer and/or ovarian cancer were identified. The pooled odds ratios (ORs) with 95 % confidence intervals 
(CIs) were used to assess the effect of gene polymorphism. And allele model, homozygous model, co-dominant model, dominant model, 
recessive model were applied.  
Result: In the overall analysis, significantly increased breast cancer and/or ovarian cancer risk was found (for allele model A VS C OR = 1.05, 
CI: 1.02-1.08, P = 4×10-3; for homozygous model AA VS CC OR = 1.11, CI: 1.03-1.19, P = 5×10-3; for recessive model (AC +AA) VS CC: OR 
= 1.10, CI: 1.03-1.18, P = 7×10-3).  
Conclusion: In the subgroup analysis, significantly increased breast cancer risk was identified among Caucasians. MTHFR A1298C 
polymorphism might contribute to an increased risk of breast cancer and/or ovarian cancer susceptibility. In addition, MTHFR A1298C 
polymorphism had a significant association with breast cancer in Caucasians. 
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Introduction 
 
Breast cancer is one of the most common cancer among women in the world, accounting for 411093 cancer deaths per year, while ovarian 
cancer is the leading cause of gynecologic cancer death worldwide (Kamangar et al., 2006; Jemal et al., 2010). There are many risk factors such 
as genetic, hormonal and environmental factors involved in the pathogenesis of breast cancer and/or ovarian cancer in women (Rizzolo et al., 
2013). Over the last few years, there was strong evidence that rare gene mutations played an important role in breast and ovarian cancer 
predisposition (Tumbull et al., 2008). For instance, the variation in the BRCA1 and BRCA2 genes is the most common genetic cause of 
hereditary forms of both breast cancer and ovarian cancer; and the prevalence of BRCA1 or BRCA2 mutation is different among ethnic groups, 
countries and regions (Gayther et al., 2010). In addition, a lot of rare variants that confer the risks of breast, ovarian cancer are discovered with 
many case-control studies. More recently, some rare gene mutations such as PPM1D, PALB2, ATM, CHEK2, BRIP1 and RAD51C gene 
involved in DNA repair were found in sporadic breast, ovarian cancer (Ruark et al., 2013). Women who carried mutations in these genes had a 
high risk of breast cancer and/or ovarian cancer. Furthermore, many molecular commonalities which were conducive to exploring related 
aetiology and similar therapeutic opportunities of breast cancer and/or ovarian cancer were found (Kobolot et al., 2012). The finding of these 
similar Molecular mutations was helpful for providing new molecular therapeutic targets (Balmana et al., 2011).  
Folate metabolism plays a crucial role in nucleic acid synthesis, methionine regeneration, oxidation and reduction reactions of one carbon 
units (Morita et al., 2013). And adequate folate intake is benefit for cell division and homeostasis. Moreover, Folates can mediate the transfer of 
one carbon units which is vital for the synthesis of S-adenosylmethionine (SAM) which offers the methyl group in the methylation reaction of 
DNA, RNA and protein (Yang et al., 2012). Therefore, the abnormity of folate metabolism will have a negative effect on the methylation and 
synthesis of DNA. Methylenetetrahydrofolate reductase (MTHFR) gene is located on the chromosome 1, which mediates the irreversible 
conversion of 5, 10-methylenetetrahydrofolate (5, 10-MTHF) to 5-methyltetrahydrofolate (5-MTHF) which is the predominant form of folate in 
plasma and provides the methyl group for de novo methionine synthesis (Zhao et al., 2011). C677T in exon 4 and A1298C in exon7 are the most 
common nucleotide polymorphisms (SNPs) in MTHFR gene. Studies have found the two polymorphisms can reduce amount of 5-MTHF and 
increase amount of 5, 10-MTHF (Jing et al., 2012). 
In recent years, several studies have been conducted to evaluate the association of gene polymorphisms with the breast cancer and/or 
ovarian cancer. But the evidence was not enough to explain the molecule origin of breast cancer and ovarian cancer. At the same time, many 
studies concerning the association of the MTHFR A1298C polymorphism with breast and/or ovarian cancer have been conducted, but the 
association between sporadic breast, ovarian cancer and Methylenetetrahydrofolate Reductase (NADPH2) gene A1298C (rs1801131) 
polymorphism remained controversial and ambiguous. Thus, to further clarify the molecule origin of breast cancer and ovarian cancer and offer 
a molecular target for molecular detection of breast cancer and/or ovarian cancer, the meta-analysis of evaluating the association between 
MTHFR A1298C polymorphism and breast, ovarian cancer was performed. 
 
 
Materials and Methods 
Publication Search Strategy 
 
Genetic association studies between breast, ovarian cancer and the MTHFR A1298C polymorphism, up to June, 2015, were retrieved by 
searching PubMed, Web of Science and CNKI (Chinese National Knowledge Infrastructure) database  with combinations of the following 
terms: "MTHFR", "A1298C", "rs1801131", "polymorphism", "SNP", "mutation", "breast carcinoma", "breast cancer", "breast neoplasm", 
"breast malignance", "ovarian carcinoma", "ovarian cancer", "ovarian neoplasm", "ovarian malignance", “breast and ovarian carcinoma”, “breast 
and ovarian cancer”. In addition, only published studies with full text articles were included. And full text of the retrieved articles was 
scrutinized to confirm that the data included could be used to perform meta-analysis. 
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Inclusion and Exclusion Criteria  
 
The inclusion criteria were as follows: (a) evaluation about the association of MTHFR A1298C polymorphism with breast cancer and/or 
ovarian cancer risk; (b) case-control studies; (c) genotype data were available for cases and controls; (d) genotype distribution of control must be 
fit in Hardy–Weinberg equilibrium (HWE).  
The exclusion criteria were as follows: (a) no detailed information of genotype data; (b) duplicate of a previously published study; (c) 
deviation from HWE in controls. 
 
Data Extraction 
 
Information was extracted from the included publications according to the inclusion criteria and the exclusion criteria. The following data 
were collected: author’s surname, year of publication, country, racial descent, cancer type, source of the control population, genotyping method 
and the frequency of genotype. Two authors independently extracted this information from all eligible studies (Table1).  
 
Table1: Characteristics of the studies included in this meta-analysis. 
Author 
Refere
nces 
Ye
ar 
Nationa
lity 
Ethnic
ity 
Cancer 
type 
Case/Co
ntrol 
Genotype(Case/Contro
l) 
Genotyping 
method 
Source of 
control 
P for 
HWE 
      
202/198 
AA AC CC 
   
Song et al [13] 
20
12 
China Asian OC 
107/1
12 
79/77 16/9 Taqman HB 0.35 
Webb et al  [14] 
20
11 
Australi
an 
Mixed OC 
1638/12
78 
770/5
98 
693/5
61 
175/1
19 
Mass 
ARRAY 
PB 0.44 
Terry et al [15] 
20
10 
USA 
Cauca
sian 
OC 
1038/10
93 
515/5
34 
430/4
50 
93/10
9 
Taqman  PB 0.32 
Terry et al [15] 
20
10 
USA 
Cauca
sian 
OC 153/484 
68/23
6 
67/20
0 
18/48 Taqman  PB 0.56 
Terry et al [15] 
20
10 
USA 
Cauca
sian 
OC 364/412 
173/1
89 
149/1
80 
42/43 Taqman  PB 0.99 
Lu et al [16] 
20
15 
China Asian BC 560/560 
369/3
52 
172/1
85 
19/23 Taqman  HB 0.83 
He et al [17] 
20
14 
China Asian BC 310/381 
138/1
73 
132/1
55 
40/53 PCR-RFLP HB 0.06 
Huang et al [18] 
20
14 
China Asian BC 
1232/12
32 
787/7
96 
386/3
91 
59/45 PCR-RFLP HB 0.72 
Wang et al [19] 
20
14 
China Asian BC 435/435 
206/2
14 
176/1
72 
53/49 PCR-RFLP HB 0.11 
Qiao et al [20] 
20
14 
China Asian BC 535/673 
258/3
51 
235/2
80 
42/42 PCR-RFLP HB 0.25 
Zheng et al [21] 
20
13 
China Asian BC 296/306 
135/1
51 
129/1
30 
32/25 PCR-RFLP HB 0.69 
Akilzhanova 
et al 
[22] 
20
13 
Kazakh
stan 
Asian BC 315/604 
138/3
18 
142/2
42 
35/44 Taqman PB 0.83 
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Wu et al [23] 
20
12 
China Asian BC 75/75 37/42 32/28 6/5 PCR-RFLP HB 0.91 
Lajin et al [24] 
20
12 
Syria Asian BC 119/126 44/65 52/48 23/13 PCR-RFLP HB 0.36 
Hua et al [25] 
20
11 
China Asian BC 95/90 50/55 42/32 3/3 PCR-RFLP PB 0.52 
Papandreou 
et al 
[26] 
20
11 
Greece 
Cauca
sian 
BC 300/283 
129/1
36 
135/1
16 
36/31 PCR-RFLP HB 0.41 
Hosseini et 
al 
[27] 
20
11 
Iran 
Cauca
sian 
BC 294/300 36/60 
96/13
5 
162/1
05 
PCR-RFLP Not stated 0.17 
Cerne et al [28] 
20
11 
Sloveni
a 
Cauca
sian 
BC 524/269 
258/1
31 
219/1
17 
47/21 Taqman HB 0.46 
Vainer et al [29] 
20
10 
Russia 
Cauca
sian 
BC 831/785 
398/3
79 
353/3
30 
80/76 PCRRFLP PB 0.74 
Ma et al [30] 
20
09 
Brazil Mixed BC 458/458 
269/2
79 
168/1
57 
21/22 Taqman  HB 0.99 
Ericson et al [31] 
20
09 
Sweden 
Cauca
sian 
BC 
541/107
2 
242/4
87 
242/4
80 
57/10
5 
Sequencing PB 0.40 
Ma et al [30] 
20
09 
Japan Asian BC 388/387 
254/2
56 
119/1
16 
15/15 Taqman HB 0.68 
Platek et al [32] 
20
09 
USA Mixed BC 
928/178
1 
443/8
42 
402/7
58 
83/18
1 
Taqman PB 0.59 
Gao et al [33] 
20
09 
China Asian BC 624/624 
446/4
25 
169/1
88 
9/11 PCR-RFLP PB 0.06 
Kotsopoulos 
et al 
[34] 
20
08 
Canada 
Cauca
sian 
BC 941/780 
466/3
98 
390/3
09 
85/73 
Mass 
ARRAY 
HB 0.25 
Inoue et al [35] 
20
08 
Singap
ore 
Asian BC 380/662 
225/3
87 
139/2
34 
16/41 PCR-RFLP PB 0.48 
Kan et al [36] 
20
07 
China Asian BC 125/101 70/61 41/32 14/8 PCR-RFLP PB 0.21 
Xu et al [37] 
20
07 
USA Mixed BC 
1062/11
03 
558/5
36 
417/4
57 
87/11
0 
Mass 
ARRAY 
PB 0.39 
Stevens et al [38] 
20
07 
USA Mixed BC 494/493 
224/2
52 
228/2
01 
42/40 PCR-RFLP PB 0.99 
Kalyankuma
r et al 
[39] 
20
06 
Indian 
Cauca
sian 
BC 88/95 49/65 33/26 6/4 PCR-RFLP Not stated 0.50 
Chou et al [40] 
20
06 
China Asian BC 142/285 
104/1
72 
30/95 8/18 PCR-RFLP HB 0.32 
Justenhoven 
et al 
[41] 
20
05 
German
y 
Cauca
sian 
BC 582/634 
273/2
95 
256/2
66 
53/73 Taqman PB 0.27 
Shrubsole et 
al 
[42] 
20
04 
China Asian BC 
1121/12
08 
768/8
24 
311/3
44 
42/40 PCR-RFLP PB 0.58 
Qi et al [43] 20 China Asian BC 217/218 155/1 58/71 4/3 PCR-RFLP PB 0.08 
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04 44 
Forsti et al [44] 
20
04 
Finland 
Cauca
sian 
BC 223/298 
94/13
3 
102/1
27 
27/38 PCR-RFLP Not stated 0.38 
Le 
Marchand et 
al 
[45] 
20
04 
USA Asian BC 318/410 
224/2
71 
83/12
6 
11/13 Taqman PB 0.72 
Le 
Marchand et 
al 
[45] 
20
04 
USA 
Cauca
sian 
BC 320/415 
160/2
11 
118/1
66 
42/38 Taqman PB 0.52 
Le 
Marchand et 
al 
[45] 
20
04 
USA 
Africa
n 
BC 246/639 
171/4
33 
68/18
7 
7/19 Taqman PB 0.83 
Le 
Marchand et 
al 
[45] 
20
04 
USA Mixed BC 236/664 
146/4
23 
77/21
2 
13/29 Taqman PB 0.71 
Le 
Marchand et 
al 
[45] 
20
04 
USA Mixed BC 69/286 
40/15
5 
25/11
0 
4/21 Taqman PB 0.81 
Ergul et al [46] 
20
03 
Turkey 
Cauca
sian 
BC 118/193 50/90 48/85 20/18 PCR-RFLP HB 0.75 
Sharp et al [47] 
20
02 
Englan
d 
Cauca
sian 
BC 55/60 27/24 25/25 3/11 PCR-RFLP HB 0.33 
OC, ovarian cancer; BC, breast cancer; HB, hospital based control; PB, population based control; Mixed, mixed population; PCR-RFLP, 
Polymerase Chain Reaction- Restriction Fragment Length Polymorphism. 
 
Statistical Analysis 
 
HWE was tested by the Chi-square test only in control groups of each study included. Crude odds ratios (ORs) with 95% confidence 
intervals (95%CIs) were used to evaluate the strength of association between MTHFR A1298C and breast cancer and/or ovarian cancer 
susceptibility. In the overall and subgroup analysis, the associations of MTHFR A1298C polymorphism with breast cancer and/or ovarian cancer 
risk were evaluated with five genetic models: homozygous model (AA VS CC), co-dominant model (AA VS AC), dominant model (AA VS (AC 
+ CC), recessive model ((AC + AA) VS CC) and allele model ( A VS C ). Subgroup analysis based on tumor type, ethnicity and source of 
control were performed. Heterogeneity was detected by the Chi-square based on Q test (P ＜ 0.05, the significant level of statistical 
heterogeneity) and I2 index (I2 ≥ 50%, the significant level of statistical heterogeneity). The random-effect model (DerSimonian et al., 1986) 
would be used if moderate or high heterogeneity existed. Otherwise, the fixed effects model (the Mantel-Haenszel method) was used (Mantel et 
al., 1959). Egger’s test and Begg’s funnel plots were performed to examine the publication bias. Sensitivity analysis was conducted by removing 
each study and observed the stability of the conclusion. Statistical analysis was carried out with STATA (Version 12.0, College Station, TX, USA) 
software. All the tests were two-sided. 
 
Results 
Study Characteristics 
 
A total of 609 relevant publications were retrieved from our initial electronic search with 5 letters, 3 case reports, 14 meta-analyses, 6 
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reviews. 143 publications were included after eliminating meta-analysis, review and scanning the title and abstract. By reading full-text, 97 
articles were excluded because they were not associated with MTHFR A1298C polymorphism and breast, ovarian cancer susceptibility or didn’t 
contain available data. 1 study was removed because of the same data in two studies. Moreover, 9 case-control studies were deviated from HWE 
and the data of 1study was inaccuracy which the number of 1298AA carriers was larger than 1298CC carriers. As a consequence, 35 studies with 
19,527 cases and 23,123 controls were finally identified in this meta-analysis. The method of literature retrieval was shown in Figure 1. Of all 
the eligible studies, there were 3 studies for ovarian cancer and 32 studies for breast cancer, while 19 researches were conducted in Asian 
populations, 15 were performed in Caucasian populations. Furthermore, the genotyping methods included TaqMan, Mass ARRAY, PCR-RFLP 
(Polymerase chain reaction- Restriction fragment length polymorphism) and Sequencing in these studies were extracted (Figure1).  
 
Figure 1: Flow diagram of literature search 
 
Quantitative Analysis 
 
Overall analysis and subgroup analysis by tumor type, ethnicity and control sources were performed to evaluate the association between 
MTHFR A1298C polymorphism and breast, ovarian cancer risk with five genetic models. In the overall analysis, statistically significant 
association between MTHFR A1298C polymorphism and breast cancer and/or ovarian cancer susceptibility was detected in three genetic models 
(allele model, A VS C OR = 1.05, CI: 1.02 - 1.08, P = 4×10-3; homozygous model, AA VS CC OR = 1.11, CI: 1.03 - 1.19, P = 5×10-3; recessive 
model, (AC + AA) VS CC OR = 1.10, CI: 1.03 - 1.18, P = 7×10-3) (Table2). In the stratified analysis by racial descent, no increased risk of breast 
cancer and/or ovarian cancer was found, while subgroup analysis by cancer type indicated a significant association between MTHFR A1298C 
polymorphism and breast cancer risk (allele model, A VS C OR = 1.04, CI: 1.00 - 1.07, P = 4×10-3; recessive model, (AC + AA) VS CC OR = 
1.10, CI: 1.01 - 1.19, P = 0.02; homozygous model, AA VS CC OR = 1.10, CI: 1.02 - 1.19, P = 0.01). In subgroup meta-analysis by cancer type 
in different ethnicity, the 1298A allele yielded a significantly increased risk for breast cancer compared to the 1298C allele in Caucasians. 
Meanwhile, no significant association with a higher breast cancer and/or ovarian cancer risk in Asian populations was found. The stratified 
analysis by control source was also conducted, significant statistical difference was found in the subgroup of control based hospital (allele model, 
A VS C OR=1.07, CI: 1.01 - 1.12, P = 0.02; recessive model, (AC + AA) VS CC OR = 1.13, CI: 1.00 - 1.28, P = 4.6×10-3; homozygous model, 
AA VS CC OR = 1.16, CI: 1.02 - 1.31, P = 0.02) (Table3). Furthermore, there is significant association between breast cancer and A1298C 
polymorphism in Caucasians (AA VS CC OR = 1.15, CI : 1.01 – 1.31, P = 0.03; (AC + AA) VS CC OR = 1.14, CI : 1.01 – 1.29, P = 0.0 3.), 
while significant association of breast cancer risk with A1298C polymorphism was revealed in the subgroup of control based hospital ( A VS C 
OR = 1.06, CI : 1.01 – 1.12, P = 0.03; AA VS CC OR = 1.14, CI : 1.01 – 1.30, P = 0.04.) (Table3). 
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Table 2: Results of Genetic Models for MTHFR A1298C Polymorphisms and breast cancer and/or ovarian cancer 
MTHFR 
A1298C 
A VS C AA VS CC AA VS (AC+CC) (AC+AA) VS CC AA VS AC 
OR/95%CI P OR/95%CI P OR/95%CI P OR/95%CI P OR/95%CI P 
Caucasian 
          
 
1.04(0.99-1.10
) 
0.1 
1.12(1.00-1.25
) 
0.05 
1.04(0.97-1.11
) 
0.3
2 
1.11(1.00-1.23
) 
0.06 
1.01(0.94-1.09
) 
0.7
1 
Asian 
          
 
1.03(0.98-1.08
) 
0.34 
1.13 
(0.99-1.28) 
0.07 
1.01(0.95-1.07
) 
0.7
8 
1.13(1.00-1.29
) 
0.06 
0.99(0.93-1.06
) 
0.7
6 
Mixed 
          
 
1.02(0.96-1.08
) 
0.51 
1.03(0.89-1.18
) 
0.72 
1.03 
(0.96-1.11) 
0.4
5 
1.01(0.89-1.16
) 
0.87 
1.03 
(0.95-1.12) 
0.4
6 
BC 
          
 
1.04(1.00-1.07
) 
0.04 
1.10(1.02-1.19
) 
0.01 
1.03 
(0.99-1.07) 
0.1
9 
1.10(1.01-1.19
) 
0.02 
1.01(0.97-1.06
) 
0.5
6 
OC 
          
 
1.02 
(0.95-1.09) 
0.64 
1.07(0.91-1.27
) 
0.41 
1.00(0.91-1.10
) 
0.9
6 
1.08 
(0.92-1.27) 
0.35 
0.99(0.89-1.09
) 
0.8 
HB 
          
 
1.07(1.01-1.12
) 
0.02 
1.16(1.02-1.31
) 
0.02 
1.07(1.00-1.14
) 
0.0
5 
1.13(1.00-1.28
) 
0.04
6 
1.05(0.98-1.12
) 
0.1
7 
PB 
          
 
1.00(0.97-1.04
) 
0.84 
1.02(0.93-1.12
) 
0.68 
1.00(0.95-1.05
) 
0.9
9 
0.98(0.90-1.07
) 
0.64 
1.00(0.95-1.05
) 
0.8
9 
Total 
          
  
1.05(1.02,1.08
) 
0.00
4 
1.11(1.03-1.19
) 
0.00
5 
1.03(0.99-1.07
) 
0.1
3 
1.10(1.03-1.18
) 
0.00
7 
1.01(0.97-1.06
) 
0.4
9 
OC, ovarian cancer; BC, breast cancer; P, P value for 2; OR, odds ratio; CI, confidence interval; Mixed, mixed population. 
 
Table 3: Subgroup analysis results based type of cancer, ethnicity and source of control for breast cancer and/or ovarian cancer. 
MTHFR 
A1298C 
  A VS C AA VS CC AA VS (AC+CC) (AC+AA) VS CC AA VS AC 
Typ
e 
OR/95%CI P OR/95%CI P OR/95%CI P OR/95%CI P OR/95%CI P 
Caucasian 
           
 
BC 
1.06(1.00-1.1
2) 
0.0
5 
1.15(1.01-1.3
1) 
0.0
3 
1.05(0.97-1.13
) 
0.2
4 
1.14(1.01-1.2
9) 
0.0
3 
1.02(0.94-1.1
1) 
0.6
3 
 
OC 
0.99(0.89-1.0
9) 
0.7
8 
0.97 
(0.77-1.22) 
0.8 
0.984(0.86-1.1
2) 
0.8
1 
0.98(0.78-1.2
2) 
0.8
3 
0.99(0.86-1.1
4) 
0.8
6 
Asian 
           
 
BC 
1.02 
(0.97-1.07) 
0.4
4 
1.11(0.97-1.2
7) 
0.1
1 
1.00(0.94-1.07
) 
0.8
9 
1.12(0.98-1.2
7) 
0.0
9 
0.99(0.92-1.0
5) 
0.7 
 
OC 1.20(0.87-1.6 0.2 1.86(0.79-4.3 0.1 1.16(0.78-1.72 0.4 1.81(0.78-4.1 0.1 1.07(0.71-1.6 0.7
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5) 6 9) 5 ) 7 9) 6 2) 3 
HB 
           
 
BC 
1.06(1.01-1.1
2) 
0.0
3 
1.14(1.01-1.3
0) 
0.0
4 
1.06(1.00-1.14
) 
0.0
7 
1.12(0.99-1.2
7) 
0.0
7 
1.05(0.98-1.1
2) 
0.1
8 
 
OC 
1.20(0.87-1.6
5) 
0.2
6 
1.86(0.79-4.3
9) 
0.1
5 
1.16(0.78-1.72
) 
0.4
7 
1.81(0.78-4.1
9) 
0.1
6 
1.07(0.71-1.6
2) 
0.7
3 
PB 
           
 
BC 
0.98(0.94-1.0
3) 
0.4
4 
0.97(0.87-1.0
8) 
0.5
5 
0.98(0.93-1.04
) 
0.4
7 
0.97(0.87-1.0
9) 
0.6
4 
0.98(0.93-1.0
4) 
0.5
4 
 
OC 
1.01(0.94-1.0
9) 
0.8
2 
1.05(0.89-1.2
4) 
0.5
8 
1.00 
(0.90-1.10) 
0.9
1 
1.06(0.90-1.2
5) 
0.5 
0.98(0.89-1.0
9) 
0.7
3 
Mixed 
           
 
BC 
0.99 
(0.92-1.06) 
0.7
4 
0.92(0.78-1.0
9) 
0.3
2 
1.01(0.92-1.10
) 
0.8
4 
0.91(0.77-1.0
7) 
0.2
4 
1.03(0.94-1.1
3) 
0.5
5 
  OC 
1.03(0.92-1.1
5) 
0.6
4 
1.14(0.88-1.4
8) 
0.3
1 
0.99(0.86-1.15
) 
0.9
1 
1.17 
(0.91-1.49) 
0.2
2 
0.96(0.82-1.1
2) 
0.6 
OC, ovarian cancer; BC, breast cancer; P, P value for 2; OR, odds ratio; CI, confidence interval; Mixed, mixed population. 
 
Heterogeneity and Sensitivity Analysis 
 
No significant heterogeneity was found in the meta-analysis. (Figure2, Figure3) Begg’s funnel plot and Egger’s test were used to evaluate 
the publication bias of the studies. No significant publication bias was found after Begg’ test and Egger’ test (for breast cancer: A VS C Begg’s 
test P=0.34, Egger’s test P=0.29; AA VS CC Begg’s test P=0.74, Egger’s test P=0.46; AA VS AC Begg’s test P=0.13, Egger’s test P=0.29; AA 
VS (AC+CC) Begg’s test P=0.09, Egger’s test P=0.14; (AC+AA) VS CC Begg’s test P=0.59, Egger’s test P=0.97; for ovarian cancer: A VS C 
Begg’s test P=0.33, Egger’s test P=0.21; AA VS CC Begg’s test P=0.62, Egger’s test P=0.37; AA VS AC Begg’s test P=0.14, Egger’s test P=0.35; 
AA VS (CA+CC) Begg’s test P=0.33, Egger’s test P=0.22; CC VS (CA+AA) Begg’s test P=0.33, Egger’s test P=0.35; for breast and/or ovarian 
cancer: A VS C Begg’s test P=0.16, Egger’s test P=0.18; AA VS CC Begg’s test P=0.59, Egger’s test P=0.30; AA VS AC Begg’s test P=0.07, 
Egger’s test P=0.17; AA VS (AC+CC) Begg’s test P=0.04, Egger’s test P=0.07; (AC+AA) VS CC Begg’s test P=0.53, Egger’s test P=0.75) 
(Figure4). The random effect model was carried out in the case of P ＜ 0.05, I2 ≥ 50%, while the fixed effect model was applied to calculate the 
ORs value and 95%CI in the genetic models of P ＞ 0.05, I2 ＜ 50%. In addition, the results were stable after sensitivity analysis. 
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Figure 2: Forest plot of MTHFR A1298C (AA VS CC) for breast cancer and/or ovarian cancer (Ethnicity) 
OR, odds ratio; 95%CI, 95% confidence interval; Mixed, mixed population 
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Figure 3: Forest plot of MTHFR A1298C (AA VS CC) for breast cancer and/or ovarian cancer (Source of control). OR, odds ratio; 95% CI, 
95% confidence interval 
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Figure 4: Begg funnel plot for publication bias test of association between MTHFR A1298C polymorphism and breast cancer and/or ovarian 
cancer. A, A VS C; B, AA VS CC; C, AA VS (AC + CC); D, (AA + AC) VS CC 
 
 
Discussion 
 
MTHFR is a key enzyme in the intracellular folate homeostasis and metabolism. A1298C (rs1801131) is one of the most common 
polymorphism of MTHFR gene, which leads to the changing of Glutamate (Glu) to Alanine (Ala). This polymorphism has been considered to 
affect the enzyme activity of MTHFR (Jing et al., 2012). Studies have suggested that the folate deficiency can influence the genetic stability of 
DNA which might increase the risk of cancer (Le et al., 2004). The small sample size of case–control studies might be a limiting factor to 
evaluate the most convinced associated loci. Studies included enough data could provide an obvious solution to increase the statistical power. A 
study performed by Gao et al. indicated that all genotype analysis showed lack of association between folate intake and MTHFR A1298C 
polymorphism in Chinese female. There was a significant association between MTHFR A1298C polymorphism and breast cancer was found 
after age adjustment (Gao et al., 2009). And the same conclusion was also displayed in Japanese population which a statistically significant 
interaction between the MTHFR A1298C polymorphism and breast cancer risk. Interestingly, vitamin B6 intake had a significant association 
with MTHFR A1298C polymorphism (Ma et al., 2009). Moreover, in the research done by Sharp et al., breast cancer risk of 1298CC carrier was 
significantly lower compared to 1298AA carrier (OR = 0.24, 95% CI: 0.06–0.97, P = 0.04) (Sharp et al., 2002).  
In contrast, the opposite result was also found in Caucasians (Forsti et al., 2004). At the same time, the contradictory conclusions also were 
exhibited in ovarian cancer. For instance, significant higher ovarian cancer risk in MTHFR 1298CC than MTHFR 1298AA was detected from 
the studies of Song et al (Song et al., 2012). Though, Terry et al. found that MTHFR SNPs A1298C were not associated with ovarian cancer risk 
in Caucasians. This study included 1642 cases and 2068 controls from three study populations and the age was corrected (Terry et al., 2010). 
And no association of MTHFR A1298C (rs1801131) with ovarian cancer risk was displayed from the UK-based GWAS (Song et al., 2009)  
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These studies got different results according to their own researches. But many environmental factors and clinical information, for example 
the sample size, disease subtype, age, hormone level and so on, would reduce the statistical power. Hence, we can’t get a convictive answer if 
MTHFR A1298C mutation will happen both in breast cancer and in ovarian cancer. So, the meta-analysis and systematic review was needed to 
resolve the problem. 
In the overall data, the results indicated that MTHFR A1298C polymorphism might be a significant risk factor for breast cancer and/or 
ovarian cancer risk. In the stratified analysis of ethnicity, compared with A allele, a significantly increased breast cancer risk was associated with 
C allele in Caucasians. Moreover, significantly increased risk was also pronounced for breast cancer in Caucasians and Asians. Meta-analysis 
has great power for analyzing cumulative data in cancer. It can investigate a large number of samples and assess the effect of genetic factors on 
disease risk. But heterogeneity often existed among studies included. So we continued to perform the subgroup analysis based cancer type after 
the subgroup analysis based ethnicity or source of control. The results revealed the significant relevance of MTHFR A1298C polymorphism with 
breast cancer risk also existed in the study which the control sample derived from hospital. In addition, the sensitivity analysis shown the results 
was stable. As a consequence, MTHFR A1298C might contribute to breast cancer risk from the subgroup analysis.  
In recent years, a lot of researches displayed that the same molecular mutations existed both in breast cancer and in ovarian cancer. In the 
meta-analysis, the carrier of MTHFR 1298CC have a higher breast cancer risk than MTHFR 1298AA carrier, especially in Caucasians. But the 
same results were not found in the studies of ovarian cancer risk. Though MTHFR A1298C is not the same molecular variation between breast 
cancer and ovarian cancer, MTHFR A1298C might be a risk factor for breast cancer risk in Caucasians. 
Cancer is one of complicated multi-genetic diseases, and different genetic background could produce obvious heterogeneity. Many factors 
could affect the precision of experimental conclusion. There are many restrictions in this study. For instance, selection criteria are different in the 
selection of control group. And many other factors such as age, tumor grade, smoking, drinking, obesity and diet could influence the occurrence 
of cancer risk. In order to eliminate the heterogeneity, we used the random-effect model and performed the subgroup analysis. In the meantime, 
we removed the studies which the genotype distribution was not consistent with the HWE to ensure the validity of the statistical results. In this 
study, the amount of ovarian cancer sample is too small. So, many comprehensive case-control studies concerning ovarian cancer are still to be 
performed in the future. 
In conclusion, MTHFR A1298C polymorphism is significantly associated with risk of breast cancer and/or ovarian cancer. Further studies 
with a large scale and considering gene-gene and gene-environment interactions should be conducted to investigate the association. 
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